Synaffix Inks Deal with MacroGenics to Enable Next Generation ADCs
- Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies
- MacroGenics to combine proprietary antibody and bispecific DART® technology with Synaffix’s linker-payload technologies to develop up to three next generation conjugates
- Total potential deal value of up to $586 million, plus royalties on commercial sales
AMSTERDAM, NETHERLANDS, February 3rd, 2022 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces it has entered into a technology agreement with MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.